<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605890</url>
  </required_header>
  <id_info>
    <org_study_id>2011-005038-20</org_study_id>
    <secondary_id>ANRS 159 VIH-2</secondary_id>
    <nct_id>NCT01605890</nct_id>
  </id_info>
  <brief_title>Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients</brief_title>
  <acronym>VIH-2</acronym>
  <official_title>ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HIV-2 is less common ie 1-2 million people in West Africa. HIV-2 does have the same
      sensitivity to antiretroviral treatment (ART) compared to HIV-1. The ART strategies that are
      appropriate for the HIV-1 infection are not as effective for HIV-2. Classical triple therapy
      including PI is less effective for HIV-2. Also, the choice of ARTs in a second line treatment
      is limited. The first line optimal treatment has to be defined by a prospective and
      randomized evaluation of other strategies. The primary endpoint will be adapted to the
      specificity of the HIV-2 infection. The 1st step is to define, with a phase II clinical
      trial, whether a strategy including 2 NRTIs and raltegravir, as an alternative strategy to
      the classical triple therapy, shows an immunovirological response, at least, as good as the
      one obtained with the triple therapy. The hypothesis is that the low ART response observed in
      HIV-2 infection is due to a low virological strength of the ARTs used and that the
      combination of 2 NRTIs and raltegravir should show a therapeutic success of at least 50% at
      week 48.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Therapeutic Success</measure>
    <time_frame>at Week 48</time_frame>
    <description>The participants will be considered in therapeutic success at Week 48 if they did not present any of the following events:
Plasma HIV-2 RNA load over or equal to 100 copies/mL, starting from Week 24 and confirmed within the next 4 weeks,
CD4 lymphocytes gain below 100/mm3 at Week 48 compared to the CD4 lymphocytes counts average between Week-4 and Week 0,
Raltegravir permanent discontinuation,
Death from any cause,
New B or C events confirmed by an endpoint review committee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Change in CD4 Lymphocytes Count at Week 12</measure>
    <time_frame>between Week 0 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinical and Biological Events</measure>
    <time_frame>from Week 0 to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change of CD4 Lymphocytes at Week 48</measure>
    <time_frame>between Week 0 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Plasma HIV-2 RNA &lt; 40 Copies/mL</measure>
    <time_frame>between Week 0 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Progression</measure>
    <time_frame>from Week 0 to Week 48</time_frame>
    <description>Clinical progression is defined as the switch:
from category A to B, C or death.
from category B to C or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Observed Percentage of Participants With Moderate to Good Adherence Evaluated With ANRS Self-administered Questionnaire of Adherence</measure>
    <time_frame>from Week 4 to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Virological Failure Participants With Resistance Mutations</measure>
    <time_frame>from Week 0 to Week 48</time_frame>
    <description>Virological failure is defined as plasma HIV-2 RNA load over or equal to 100 copies/mL after plasma HIV-2 RNA load below 100copies/mL, confirmed with a retest within the 4 following weeks. The number and type of mutations in the RT and integrase genes compared to week 0 is being reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Switch or Discontinuation</measure>
    <time_frame>from Week 0 to Week 48</time_frame>
    <description>Overall (regardless of the molecule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With &gt;6 Copies of HIV-2 DNA in Plasma at Week 48</measure>
    <time_frame>at Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Median of the Lower Dimension Out of the 4 Dimensions of the Quality of Life Questionnaire</measure>
    <time_frame>from Week 0 to Week 48</time_frame>
    <description>The quality of life questionnaire is the Professional Quality of Life (PROQOL) questionnaire, including 4 dimensions:
Physical health and symptoms, Relationship with others, Mental and cognitive functioning and Treatment impact For each scale, a score ranging from 0 (the worst answer) to 100 (the best answer) is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With &gt;6 Copies of HIV-2 DNA in Plasma at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV-2 Infection</condition>
  <arm_group>
    <arm_group_label>raltegravir / emtricitabine / tenofovir disoproxil fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine / tenofovir disoproxil fumarate / raltegravir .</intervention_name>
    <description>emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
    <arm_group_label>raltegravir / emtricitabine / tenofovir disoproxil fumarate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥18 years

          -  HIV-2 mono infection, confirmed by ELISA and Western Blot test or Immunoblot,

          -  antiretroviral treatment-naive, whatever the duration and indication of prior
             treatments,

          -  indication to treatment, with at least one of the following criteria : type B or C
             events, CD4 lymphocytes count below 500/mm3 at screening-visit or CD4 lymphocytes
             count decrease of at least 50 cell/µL/year over the last 3 years with the last CD4
             lymphocytes count within -/+ 10 % of the nadir, plasma HIV-2 RNA load over or equal to
             100 copies/mL at screening-visit,

          -  Pneumocystis prophylaxis if CD4 lymphocytes count below 200/mm3, combined to a
             toxoplasmosis prophylaxis in case of a positive toxoplasmosis serology,

          -  French residency for at least one year,

          -  Written informed consent, signed by the participant and the investigator (at the
             latest on the screening-visit and prior any study related intervention)

          -  Affiliate or beneficiary of a social security system (State Medical Assistance is not
             a social security scheme).

        Exclusion Criteria:

          -  Absence of effective contraception method(women),

          -  Pregnancy, breastfeeding or wish for pregnancy during the trial,

          -  Curative treatment of a progressive opportunistic infection not compatible with those
             evaluated in the present study,

          -  Malignant or tumorous affection requiring chemotherapy or radiotherapy,

          -  Decompensated cirrhosis,

          -  Viral hepatitis C with a Metavir score over F2,

          -  Hemoglobinemia below 7g/dL, polynuclear neutrophils below 500/mm3, platelets below 50
             000/mm3, creatinine clearance below 50 mL/mn, transaminase, alkaline phosphatase or
             bilirubin over 2.5N,

          -  Contraindication to one of the excipients of study treatments,

          -  Insuline-dependent diabetes mellitus not well controlled (with glycated haemoglobin
             (HbA1C) over 7%),

          -  Long-term corticosteroid treatment (more than 3 weeks of treatment),

          -  Judicial protection, legal guardianship,

          -  Participation in other therapeutic trial or comprising an exclusion period ongoing at
             the time of the screening-visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Matheron, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Bichat-Claude Bernard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>September 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2018</results_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled ART-naïve adults infected with HIV-2 only with history of CDC group B or C event, or a CD4 count &lt;500 cells/μL, or a CD4 decrease &gt;50 cells/μL/year over the past 3 years, or a confirmed plasma HIV-2 RNA (pVL) ≥100 copies (cp) /mL from 18 hospital centers in France.The last participant completed in December 2015.</recruitment_details>
      <pre_assignment_details>Of the 38 participants screened between July 2012 and January 2015, 30 (78.9%) participants were finally included.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
          <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
          <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" lower_limit="46.0" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Therapeutic Success</title>
        <description>The participants will be considered in therapeutic success at Week 48 if they did not present any of the following events:
Plasma HIV-2 RNA load over or equal to 100 copies/mL, starting from Week 24 and confirmed within the next 4 weeks,
CD4 lymphocytes gain below 100/mm3 at Week 48 compared to the CD4 lymphocytes counts average between Week-4 and Week 0,
Raltegravir permanent discontinuation,
Death from any cause,
New B or C events confirmed by an endpoint review committee</description>
        <time_frame>at Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Therapeutic Success</title>
          <description>The participants will be considered in therapeutic success at Week 48 if they did not present any of the following events:
Plasma HIV-2 RNA load over or equal to 100 copies/mL, starting from Week 24 and confirmed within the next 4 weeks,
CD4 lymphocytes gain below 100/mm3 at Week 48 compared to the CD4 lymphocytes counts average between Week-4 and Week 0,
Raltegravir permanent discontinuation,
Death from any cause,
New B or C events confirmed by an endpoint review committee</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="22.7" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in CD4 Lymphocytes Count at Week 12</title>
        <time_frame>between Week 0 and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in CD4 Lymphocytes Count at Week 12</title>
          <units>cells/µL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="2" upper_limit="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinical and Biological Events</title>
        <time_frame>from Week 0 to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinical and Biological Events</title>
          <units>clinical and biological events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change of CD4 Lymphocytes at Week 48</title>
        <time_frame>between Week 0 and Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change of CD4 Lymphocytes at Week 48</title>
          <units>cells/µL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="38" upper_limit="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Plasma HIV-2 RNA &lt; 40 Copies/mL</title>
        <time_frame>between Week 0 and Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Plasma HIV-2 RNA &lt; 40 Copies/mL</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Progression</title>
        <description>Clinical progression is defined as the switch:
from category A to B, C or death.
from category B to C or death.</description>
        <time_frame>from Week 0 to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Progression</title>
          <description>Clinical progression is defined as the switch:
from category A to B, C or death.
from category B to C or death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Observed Percentage of Participants With Moderate to Good Adherence Evaluated With ANRS Self-administered Questionnaire of Adherence</title>
        <time_frame>from Week 4 to Week 48</time_frame>
        <population>Number of participants with available questionnaire of adherence</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Observed Percentage of Participants With Moderate to Good Adherence Evaluated With ANRS Self-administered Questionnaire of Adherence</title>
          <population>Number of participants with available questionnaire of adherence</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Virological Failure Participants With Resistance Mutations</title>
        <description>Virological failure is defined as plasma HIV-2 RNA load over or equal to 100 copies/mL after plasma HIV-2 RNA load below 100copies/mL, confirmed with a retest within the 4 following weeks. The number and type of mutations in the RT and integrase genes compared to week 0 is being reported.</description>
        <time_frame>from Week 0 to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Virological Failure Participants With Resistance Mutations</title>
          <description>Virological failure is defined as plasma HIV-2 RNA load over or equal to 100 copies/mL after plasma HIV-2 RNA load below 100copies/mL, confirmed with a retest within the 4 following weeks. The number and type of mutations in the RT and integrase genes compared to week 0 is being reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Switch or Discontinuation</title>
        <description>Overall (regardless of the molecule)</description>
        <time_frame>from Week 0 to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Switch or Discontinuation</title>
          <description>Overall (regardless of the molecule)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With &gt;6 Copies of HIV-2 DNA in Plasma at Week 48</title>
        <time_frame>at Week 48</time_frame>
        <population>Participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &gt;6 Copies of HIV-2 DNA in Plasma at Week 48</title>
          <population>Participants with available measurements</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Median of the Lower Dimension Out of the 4 Dimensions of the Quality of Life Questionnaire</title>
        <description>The quality of life questionnaire is the Professional Quality of Life (PROQOL) questionnaire, including 4 dimensions:
Physical health and symptoms, Relationship with others, Mental and cognitive functioning and Treatment impact For each scale, a score ranging from 0 (the worst answer) to 100 (the best answer) is calculated.</description>
        <time_frame>from Week 0 to Week 48</time_frame>
        <population>Participants with available PROQOL questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Median of the Lower Dimension Out of the 4 Dimensions of the Quality of Life Questionnaire</title>
          <description>The quality of life questionnaire is the Professional Quality of Life (PROQOL) questionnaire, including 4 dimensions:
Physical health and symptoms, Relationship with others, Mental and cognitive functioning and Treatment impact For each scale, a score ranging from 0 (the worst answer) to 100 (the best answer) is calculated.</description>
          <population>Participants with available PROQOL questionnaire</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="20" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With &gt;6 Copies of HIV-2 DNA in Plasma at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>Participants with available measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
            <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &gt;6 Copies of HIV-2 DNA in Plasma at Week 24</title>
          <population>Participants with available measurement</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir / Emtricitabine / Tenofovir Disoproxil Fumarate</title>
          <description>emtricitabine / tenofovir disoproxil fumarate / raltegravir .: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Helicobacter pylori gastritis, Escherichia coli cystitis</sub_title>
                <description>Also functionnal colopathy referring to the SOC=Gastrointestinal disorders</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Truvada overdose without any adverse event</sub_title>
                <description>Other medically important condition</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar ischemic stroke</sub_title>
                <description>Hospitalisation or prolongation of existing Hospitalisation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Suspected recurrence of bronchopulmonary cancer</sub_title>
                <description>Hospitalisation or prolongation of existing Hospitalisation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Leuco-neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Backache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr Sophie Matheron</name_or_title>
      <organization>Hopital Bichat-Claude Bernard, AP-HP, Paris, France</organization>
      <phone>+33140257883</phone>
      <email>sophie.matheron@aphp.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

